ENTA 86,77$ (+4%)

Enanta meldet Zahlen für das Dezember-Quartal 2018

• Umsatz ~70 Mio. $
  
• Gewinn ~26 Mio. $
  
• EPS ~1,25 $
  

https://www.enanta.com/investors/news-releases/...1-2018/default.aspx

 

Enante meldet Zahlen für das März-Quartal 2019

• Umsätze 40 Mio. $
  
• Gewinn 4 Mio. $
  
• EPS 0,20 $
  

"Data from Phase 2a RSV program anticipated mid-2019 and Phase 2a NASH program by the end of third quarter of calendar 2019"

 https://www.enanta.com/investors/news-releases/...1-2019/default.aspx

 

Enanta meldet Zahlen für Q2/19

• Umsatz 44 Mio. $
  
• Gewinn 7 Mio. $
  
• EPS 0,33$
  

https://www.enanta.com/investors/news-releases/...0-2019/default.aspx

 

NASH Studienergebnisse EDP-305

https://www.enanta.com/investors/news-releases/...f-NASH/default.aspx

https://xconomy.com/boston/2019/09/26/...race-with-unclear-prospects/

https://endpts.com/...drug-barely-meets-main-goal-in-mid-stage-study/

 

rückläufige Lizenzeinnahmen im Sept-Quartal 2019 (von AbbVie´s Maviret/Mavyret)

https://www.enanta.com/investors/news-releases/...0-2019/default.aspx

 

Sucht noch seinen Boden, bin mal gespannt ob die 50$ kurzfristig halten werden, ich tippe auf "nein".  

Zahlen für das Dezember-Quartal 2019

• Umsatz 52,6 Mio. $
  
• Gewinn 13,4 Mio. $
  
• EPS 0,65$
  
• Cash 415 Mio. $
  
• MK 1,105 Mrd. $
  

https://www.enanta.com/investors/news-releases/...1-2019/default.aspx

 

https://m.benzinga.com/article/15546603

 

Zahlen für das Juni-Quartal 2020

• Umsatz 19 Mio. $
  
• Verlust 14 Mio. $
  
• EPS -0,71$
  
• Cash 435 Mio. $
  
• MK 1,00 Mrd. $
  

"Total revenue of $18.7 million for the three months ended June 30, 2020 consisted of royalty revenue derived primarily from worldwide net sales of AbbVie’s hepatitis C virus (HCV) regimen MAVYRET^®/MAVIRET^®. For the three months ended June 30, 2019, total revenue was $44.4 million, which consisted of royalty revenue earned on AbbVie’s global net sales of its HCV regimens. AbbVie has stated that the decrease in royalty revenue in the three months ended June 30, 2020 was mainly driven by declining treated patient volumes due to the COVID-19 pandemic."

https://www.enanta.com/investors/news-releases/....m.-ET/default.aspx

 

Bin gespannt ob die 40$ Marke halten wird & wie hoch die Royalty Umsätze in Q3/20 ausgefallen sind.

• MK 884 Mio. $
  

 

Zahlen für das September-Quartal 2020

• Umsatz 24 Mio. $
  
• operativer Verlust 20 Mio. $
  
• Verlust 29 Mio. $
  
• Cash 419 Mio. $
  
• MK 827 Mio. $
  

"Total revenue of $23.6 million for the three months ended September 30, 2020 consisted of royalty revenue derived primarily from worldwide net sales of AbbVie’s hepatitis C virus (HCV) regimen MAVYRET®/MAVIRET® (glecaprevir/pibrentasvir). Total revenue for the three months ended September 30, 2019, was $51.3 million. For the twelve months ended September 30, 2020, total revenue was $122.5 million compared to $205.2 million for the same period in 2019. The decrease in royalty revenue quarter over quarter was driven by lower HCV product sales as treated patient volumes have remained below pre-COVID levels, as reported by AbbVie."

https://www.enanta.com/investors/news-releases/...0-2020/default.aspx

 

Zahlen für das März-Quartal 2022

• Umsatz 19 Mio. $
  
• Verlust 34 Mio. $
  
• Cash 323 Mio. $
  
• MK 952 Mio. $
  

https://ir.enanta.com/news-releases/...inancial-results-its-fiscal-31

EDP-938 verfehlt den primären Endpunkt in Phase2b Studie

https://www.benzinga.com/general/biotech/22/05/...ss-primary-endpoint

 

EDP-235 (Covid-Pille)

• reduzierte einige Symptome der Atemwegserkrankung
  
• verringerte jedoch weder die Viruslast
  
• noch die Zeit bis zur Besserung im Vergleich zu Placebo
  

https://www.fiercebiotech.com/biotech/...ata-hopes-attracting-partner